Entrada Therapeutics (TRDA) Surges 8.9%: Is This an Indication of Further Gains?Zacks Investment Research • 05/05/26
Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewsWire • 02/26/26
Earnings Preview: Entrada Therapeutics, Inc. (TRDA) Q4 Earnings Expected to DeclineZacks Investment Research • 02/19/26
Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics' ELEVATE-44-201 StudyGlobeNewsWire • 02/17/26
Entrada Therapeutics, Inc. (TRDA) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/15/26
Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular DiseasesGlobeNewsWire • 01/08/26
Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 12/17/25
Entrada Therapeutics: Soft Q3 Earnings, But Builds Momentum Toward 2026 ReadoutsSeeking Alpha • 11/17/25
Entrada Therapeutics Announces Recipients of Third Annual DREAMS Grant ProgramGlobeNewsWire • 09/05/25
Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/06/25
Entrada Therapeutics (TRDA) Soars 5.6%: Is Further Upside Left in the Stock?Zacks Investment Research • 07/31/25
Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of DirectorsGlobeNewsWire • 06/03/25
Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 SkippingGlobeNewsWire • 05/28/25
Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/08/25
Analysts Estimate Entrada Therapeutics, Inc. (TRDA) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 04/29/25
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 SkippingGlobeNewsWire • 03/24/25
Entrada Therapeutics, Inc. (TRDA) Surpasses Q4 Earnings and Revenue EstimatesZacks Investment Research • 02/27/25
Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewsWire • 02/27/25